0000000000368548

AUTHOR

C. Vidal

showing 18 related works from this author

A time to look back: analysis of morphokinetic characteristics of human embryo development.

2013

Objective To describe the times associated with the morphological changes that occur in the embryo during preimplantation development based on the largest sample size described with time lapse. Design Cohort study. Setting University-affiliated private center. Patient(s) A total of 9,530 embryos from 1,806 intracytoplasmic sperm injection (ICSI) cycles. Intervention(s) None. Main Outcome Measure(s) Using a time-lapse system, embryo images were acquired for at least 68 hours, in some cases reaching 120–130 hours. Embryo cleavage time points up to 8-cell-stage (t2–t8) as well as morulae (tM) and blastocyst formation (tB) were registered in hours after ICSI. Additionally, duration of the cell …

medicine.medical_specialtymedicine.medical_treatmentPopulationEmbryonic DevelopmentBiologyCleavage (embryo)Time-Lapse ImagingIntracytoplasmic sperm injectionBack analysismedicineHumansBlastocystSperm Injections IntracytoplasmiceducationCells CulturedGynecologyeducation.field_of_studyEmbryogenesisCell CycleObstetrics and GynecologyEmbryoEmbryo Mammalianmedicine.anatomical_structureBlastocystReproductive MedicineEmbryologyembryonic structuresFertility and sterility
researchProduct

Defining new morphokinetic variables for embryo selection by time-lapse

2012

Reproductive MedicineObstetrics and GynecologyEmbryoComputational biologyBiologySelection (genetic algorithm)Fertility and Sterility
researchProduct

Hard Two-Photon Contribution to Elastic Lepton-Proton Scattering Determined by the OLYMPUS Experiment

2017

The OLYMPUS collaboration reports on a precision measurement of the positron-proton to electron-proton elastic cross section ratio, $R_{2\gamma}$, a direct measure of the contribution of hard two-photon exchange to the elastic cross section. In the OLYMPUS measurement, 2.01~GeV electron and positron beams were directed through a hydrogen gas target internal to the DORIS storage ring at DESY. A toroidal magnetic spectrometer instrumented with drift chambers and time-of-flight scintillators detected elastically scattered leptons in coincidence with recoiling protons over a scattering angle range of $\approx 20\degree$ to $80\degree$. The relative luminosity between the two beam species was mo…

ratioPhysics::Instrumentation and DetectorsHadronFOS: Physical sciencesSocio-culturaleGeneral Physics and AstronomyElectron01 natural sciencestransfersNuclear physicsEconomica0103 physical sciencesddc:550electromagnetic form factorsNuclear Experiment (nucl-ex)010306 general physicselectromagnetic form factors transfers ratioNuclear ExperimentPhysicsLuminosity (scattering theory)010308 nuclear & particles physicsScatteringGenerator (category theory)Form factor (quantum field theory)BremsstrahlungHigh Energy Physics::ExperimentLeptonPhysical Review Letters
researchProduct

Archaeometric study of ceramic figurines from the Maya settlement of La Blanca (Petén, Guatemala)

2014

Abstract In this article, analytical results will be presented and discussed regarding a selected set of figurines from the ancient Maya settlement of La Blanca in Peten, Guatemala. The objective is to characterize the ceramic material by two analytical complementary techniques: X-ray diffraction (XRD) and total reflection X-ray fluorescence (TXRF). The data obtained by means of both XRD and TXRF were compared and analyzed by multivariate statistical techniques in order to obtain sample groups according to their chemical composition. The results of this archaeometric study have been compared to those that have been obtained through macroscopic characterization by means of the traditional cl…

RadiationSettlement (structural)visual_artvisual_art.visual_art_mediumMayaCeramicMultivariate statisticalArchaeologyAncient mayaGeologyMultivariate classificationRadiation Physics and Chemistry
researchProduct

Prospective, randomized study of the endometrial receptivity analysis (ERA) test in the infertility work-up to guide personalized embryo transfer ver…

2016

0301 basic medicineInfertilityGynecologymedicine.medical_specialty030219 obstetrics & reproductive medicineObstetricsbusiness.industryObstetrics and Gynecologymedicine.diseaseEmbryo transferWork-upTest (assessment)03 medical and health sciences030104 developmental biology0302 clinical medicineReproductive MedicinemedicineProspective randomized studyEndometrial receptivitybusinessFertility and Sterility
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

2020

Abstract Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed …

Male0301 basic medicinePsychological interventionHuman immunodeficiency virus (HIV)MedizinContinuum of care; Europe; HIV infection; Key population; Sex; Anti-Retroviral Agents; Continuity of Patient Care; European Union; HIV; Humans; Male; HIV InfectionsHIV InfectionsContinuum of care; Europe; HIV infection; Key population; Sexmedicine.disease_causekey population0302 clinical medicineContinuum of careHIV Infection030212 general & internal medicineMen having sex with menContinuum of caremedia_commoneducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTransmission (medicine)Continuity of Patient CareEuropeInfectious DiseasesAcademicSubjects/MED00290Anti-Retroviral AgentsHIV infection continuum of care sex key population EuropeSexMicrobiology (medical)PopulationSocio-culturale03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationPandemicsHIV infection ; continuum of care ; sex ; key population ; Europebusiness.industrySARS-CoV-2COVID-19HIVmedicine.diseaseHIV infectioncontinuum of care030112 virologyMajor Articles and CommentariesKey populationAnti-Retroviral Agentbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemography
researchProduct

A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF.

2020

Abstract Research question Does clinical performance of personalized embryo transfer (PET) guided by endometrial receptivity analysis (ERA) differ from frozen embryo transfer (FET) or fresh embryo transfer in infertile patients undergoing IVF? Design Multicentre, open-label randomized controlled trial; 458 patients aged 37 years or younger undergoing IVF with blastocyst transfer at first appointment were randomized to PET guided by ERA, FET or fresh embryo transfer in 16 reproductive clinics. Results Clinical outcomes by intention-to-treat analysis were comparable, but cumulative pregnancy rate was significantly higher in the PET (93.6%) compared with FET (79.7%) (P = 0.0005) and fresh embr…

Endometrial receptivity analysis (ERA)Adultmedicine.medical_specialtyPregnancy Rateendometrial receptivityFresh embryo transfer (ET)Fertilization in Vitrolaw.inventionRandomized controlled triallawPregnancyMedicineHumansBirth RateGynecologyCryopreservationPregnancyPersonalized embryo transfer (PET)Intention-to-treat analysisbusiness.industryBlastocyst TransferObstetrics and Gynecologymedicine.diseaseEmbryo TransferEmbryo transferPregnancy rateTreatment OutcomeReproductive MedicineFrozen embryo transfer (FET)embryonic structuresFemaleEndometrial receptivityWindow of implantation (WOI)Live birthbusinessInfertility FemaleLive BirthDevelopmental BiologyReproductive biomedicine online
researchProduct

Mitochondrial DNA content decreases during in vitro human embryo development: insights into mitochondrial DNA variation in preimplantation embryos do…

2020

Objective To assess the mitochondrial DNA (mtDNA) load and variation in human oocytes and during preimplantation embryo development using specimens donated for research. Design Prospective cohort study. Setting Not applicable. Patients A total of 50 in vitro fertilization patients and 11 oocyte donors whose specimens were obtained between July 2017 and July 2018. Interventions None. Main Outcome Measures All specimens were separately collected. Quantitative polymerase chain reaction was performed with SurePlex DNA Amplification System (Illumina). Primers for the adenosine triphosphate 8 mitochondrial gene and the β-actin were used. Data were statistically analyzed by analysis of variance wi…

AndrologyMitochondrial DNAReal-time polymerase chain reactionmedicine.anatomical_structureHuman fertilizationEmbryogenesismedicineEmbryo cultureEmbryoBlastocystBiologyOocyteFS science
researchProduct

Measurement of the Charge-Averaged Elastic Lepton-Proton Scattering Cross Section by the OLYMPUS Experiment

2020

Physical review letters 126(16), 162501 (1-6) (2021). doi:10.1103/PhysRevLett.126.162501

ProtonPhysics::Instrumentation and Detectorselectromagnetic [calorimeter]elastic scatteringGeneral Physics and AstronomyElectronmomentum transfer dependence01 natural sciencesEconomicaelectromagnetic form factorsDESY LabNuclear Experiment (nucl-ex)Nuclear ExperimentNuclear ExperimentPhysicsElastic scatteringLuminosity (scattering theory)Form factor (quantum field theory)elastic scattering [cross section]recoil [p]beam [positron]target [hydrogen]electromagnetic [form factor]electron-proton scatteringSocio-culturaleFOS: Physical sciences530electron p: scatteringNuclear physicsCross section (physics)PE2_2PE2_10103 physical sciencesform factor [p]p: recoilddc:530cross section: elastic scattering010306 general physicsPE2_3hydrogen: targetNuclear Physicspositron p: scatteringAmbientalepositron-proton scatteringDESYscattering [electron p]form factor: electromagneticscattering [positron p]positron: beamcalorimeter: electromagneticp: form factorPhysics::Accelerator PhysicsHigh Energy Physics::Experimentspectrometerexperimental resultsLeptonPhysical Review Letters
researchProduct

GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controll…

2009

Objective To assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles. Design Single-center, randomized, single-blind, placebo-controlled trial. Setting University-affiliated infertility clinic, between February 2005 and December 2007. Patient(s) Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication. Intervention(s) Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n = 172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time. Main Outcome Measure(s) Pregnancy rate was the primary outcom…

AdultMalemedicine.medical_specialtyTime FactorsPregnancy Ratemedicine.medical_treatmentLuteal phaseDrug Administration Schedulelaw.inventionMiscarriageGonadotropin-Releasing HormonePlacebosRandomized controlled triallawPregnancyMedicineHumansSingle-Blind MethodEmbryo ImplantationInsemination ArtificialGynecologyPregnancyTriptorelin Pamoatebusiness.industryObstetricsArtificial inseminationUterusPregnancy OutcomeObstetrics and GynecologyFertility Agents Femalemedicine.diseaseTriptorelinPregnancy rateReproductive MedicineGestationFemalebusinessAlgorithmsmedicine.drugFertility and sterility
researchProduct

Gene polymorphisms and HLA-G expression in spontaneous abortions

2015

Abstract Introduction HLA-G and HLA-E are claimed to play a role in establishing maternal–fetal immune tolerance and in maintaining pregnancy. The presence of polymorphism in the HLA-G gene could cause a deficient or excessive expression of the HLA-G and HLA-E molecules. These anomalies could eventually cause pregnancy losses. Materials and methods Clinical study. A total of 90 patients were included in this study. These patients suffered spontaneous abortions between weeks 6 and 11 of pregnancy. We have analysed the most important polymorphisms of the HLA-G gene through different genetic studies and HLA-G and HLA-E expression through immunostaining in human cytotrophoblast cells from first…

PregnancyCytotrophoblastKaryotypeHuman leukocyte antigenBiologyAbortionmedicine.diseaseImmune toleranceAndrologymedicine.anatomical_structureHLA-GImmunologymedicineImmunostainingMedicina Reproductiva y Embriología Clínica
researchProduct

F117Hystero-embryoscopic findings in early nonviable pregnancies

2000

Background A high proportion of early pregnancy losses are associated to abnormal embryo development. However, chromosomal analysis of routine curettage samples are of limited value; and histopathological examinations of the embryos are rarely performed in clinical practice. Method A transcervical hystero-embryoscopy was performed prior to the curettage in 31 nonviable first-trimester pregnancies and a control group of 5 early terminations of pregnancy. In the study group, the estimated gestational age according to the ultrasound findings was 6.7 (4–9) menstrual weeks. Direct biopsies of different gestational structures were taken during the endoscopic procedure. Results In nonviable pregna…

Gynecologymedicine.medical_specialtyPregnancyRadiological and Ultrasound Technologybusiness.industryObstetricsmedicine.medical_treatmentGestational sacObstetrics and GynecologyGeneral Medicinemedicine.diseaseUmbilical cordCurettagemedicine.anatomical_structureReproductive MedicineDecidua Capsularisembryonic structuresmedicineGestationChorionic villiRadiology Nuclear Medicine and imagingYolk sacbusinessUltrasound in Obstetrics and Gynecology
researchProduct

Operation and characterization of a windowless gas jet target in high-intensity electron beams

2021

Abstract A cryogenic supersonic gas jet target was developed for the MAGIX experiment at the high-intensity electron accelerator MESA. It will be operated as an internal, windowless target in the energy-recovering recirculation arc of the accelerator with different target gases, e.g., hydrogen, deuterium , helium, oxygen, argon, or xenon. Detailed studies have been carried out at the existing A1 multi-spectrometer facility at the electron accelerator MAMI. This paper focuses on the developed handling procedures and diagnostic tools, and on the performance of the gas jet target under beam conditions. Considering the special features of this type of target, it proves to be well suited for a n…

Nuclear and High Energy PhysicsPhysics - Instrumentation and DetectorsNuclear engineeringchemistry.chemical_elementFOS: Physical sciencesElectron01 natural scienceslaw.inventionXenonlaw0103 physical sciencesNuclear Experiment (nucl-ex)010306 general physicsInstrumentationNuclear ExperimentHeliumPhysicsJet (fluid)Argon010308 nuclear & particles physicsParticle acceleratorInstrumentation and Detectors (physics.ins-det)chemistryPhysics::Accelerator PhysicsElectron scatteringBeam (structure)
researchProduct

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

The OLYMPUS Experiment

2014

Nuclear instruments & methods in physics research / A 741, 1 - 17 (2014). doi:10.1016/j.nima.2013.12.035

two-photon [exchange]Physics - Instrumentation and DetectorsPhysics::Instrumentation and DetectorsHadronluminosity: monitoringRecoil4-MOMENTUM TRANSFERSNuclear Experiment (nucl-ex)Nuclear ExperimentInstrumentationNuclear ExperimentPhysicsElastic scatteringLuminosity (scattering theory)ELECTROMAGNETIC FORM-FACTORSInstrumentation and Detectors (physics.ins-det)elastic scattering [cross section]positron p: elastic scatteringAntimatterdrift chamberelastic scattering [electron p]target [hydrogen]proportional chamberCROSS-SECTIONNuclear and High Energy PhysicsELECTRON-PROTONDESY DORIS StorFOS: Physical sciencesmonitoring [luminosity]time-of-flight530electron p: elastic scatteringNuclear physicsCross section (physics)RATIO(GEV/C)(2)p: form factor: ratiocalorimeterddc:530cross section: elastic scatteringactivity reporthydrogen: targetexchange: two-photonScatteringPOSITRONSDESYelastic scattering [positron p]magnetic spectrometerELECTROMAGNETIC FORM-FACTORS; PROTON ELASTIC-SCATTERING; 4-MOMENTUM TRANSFERS; ELECTRON-PROTON; CROSS-SECTION; RATIO; (GEV/C)(2); POSITRONSform factor: ratio [p]gas electron multiplierPhysics::Accelerator PhysicsPROTON ELASTIC-SCATTERINGHigh Energy Physics::Experiment
researchProduct

Design and Operation of a Windowless Gas Target Internal to a Solenoidal Magnet for Use with a Megawatt Electron Beam

2019

A windowless hydrogen gas target of nominal thickness $10^{19}$ cm$^{-2}$ is an essential component of the DarkLight experiment, which is designed to utilize the megawatt electron beam at an Energy Recovery Linac (ERL). The design of such a target is challenging because the pressure drops by many orders of magnitude between the central, high-density section of the target and the surrounding beamline, resulting in laminar, transitional, and finally molecular flow regimes. The target system was assembled and operated at Jefferson Lab's Low Energy Recirculator Facility (LERF) in 2016, and subsequently underwent several revisions and calibration tests at MIT Bates in 2017. The system at dynamic…

Nuclear and High Energy PhysicsPhysics - Instrumentation and DetectorsOrders of magnitude (temperature)Windowless gas targetNuclear engineeringDarkLightFOS: Physical sciences[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]01 natural sciences7. Clean energyCOMSOLFree molecular flow0103 physical sciencesCalibration[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]Nuclear Experiment (nucl-ex)010306 general physicsInstrumentationNuclear ExperimentPhysicsSolenoidal vector field010308 nuclear & particles physicsLaminar flowDark photonInstrumentation and Detectors (physics.ins-det)BeamlineMagnetCathode ray
researchProduct

Analysis of serum and endometrial progesterone in determining endometrial receptivity.

2021

Abstract STUDY QUESTION Is there a relationship between serum and endometrial progesterone (P4) levels, including P4 and metabolites (oestrone, oestradiol and 17α-hydroxyprogesterone), and endometrial receptivity? SUMMARY ANSWER Serum P4 levels were not correlated with endometrial P4, nor associated with endometrial receptivity as determined by the ERA® test; however, endometrial P4 and 17α-hydroxyprogesterone levels were positively correlated and related to endometrial receptivity by ERA. WHAT IS KNOWN ALREADY Acquisition of endometrial receptivity is governed by P4, which induces secretory transformation. A close relationship between serum P4 and pregnancy outcome is reported for hormone …

Adultmedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentPopulationUterusLuteal phaseEndometriumEndometriumPregnancyMedicine17a-hydroxyprogesterone ERA test P4 endometrial receptivity progesterone steroid hormones metabolitesHumansEmbryo ImplantationProspective StudieseducationProspective cohort studyProgesteroneGynecologyeducation.field_of_studyPregnancymedicine.diagnostic_testbusiness.industryRehabilitationObstetrics and GynecologyHormone replacement therapy (menopause)medicine.diseaseEmbryo Transfermedicine.anatomical_structureReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct